Sample · CapitalDart Contact
Sarah Chen · Stonecreek Capital Partners
A fictional investor contact showing firm details, fit rationale, and AI-drafted outreach across channels.
Sarah Chen
- AUM
- $1.2B
- Location
- Boston, MA, US
- Strategic
- No
- # Investments 2yr
- 22
- Professionals
- 18
Boston-based healthcare and biotech specialist deploying growth-stage capital into clinical-stage therapeutic platforms. Twenty-two transactions over the trailing two years across gene therapy, cell therapy, and precision oncology. Typical check size $10-50M with leadership preference. Active board involvement and dedicated CMC operating talent in-house. Investment committee meets weekly; decisions historically inside six weeks of first meeting.
Boston-based healthcare-focused MD at Stonecreek with track record in gene therapy and clinical-stage biotech. Recently led SyntheNeural Series C; profile matches Solstice's stage and sector exactly.
Initial outreach
Hi Sarah, Reaching out on a $30M Series C for Solstice BioTherapeutics, a clinical-stage gene therapy platform with two assets in Phase 2. Lead investor wrote $12M and we have $18M open. Stonecreek's recent bio investments track this profile closely. Quick call Tuesday or Wednesday to walk through the deck? Best, Alex
Sarah, sending a $30M Series C deck for a Phase 2 gene therapy platform. Lead committed, $18M open. Please let me know a time that works for a call.